Research
Epitranscriptomics & Cancer Adaptation : A.David

Activities

Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.

More..

Zotero public









Cancel


13 Items
Title  Creator  Group name  Publishing year 
The Hippo pathway terminal effector TAZ/WWTR1 mediates oxaliplatin sensitivity in p53 proficient colon cancer cells Slaninová et al. EquipeAD 2024-05-14
Modulation of the Estrogen/erbB2 Receptors Cross-talk by CDK4/6 Inhibition Triggers Sustained Senescence in Estrogen Receptor- and ErbB2-positive Breast Cancer Viganò et al. EquipeCG 2022-05-13
First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma Italiano et al. EquipeCG 2022-02
Anti-tumoral activity of the Pan-HER (Sym013) antibody mixture in gemcitabine-resistant pancreatic cancer models Rabia et al. EquipeCG 2021 Jan-Dec
Higher Anti-Tumor Efficacy of the Dual HER3-EGFR Antibody MEHD7945a Combined with Ionizing Irradiation in Cervical Cancer Cells Bourillon et al. EquipeAP Jan 17, 2020
MESOTIP: Phase II multicenter randomized trial evaluating the association of PIPAC and systemic chemotherapy vs. systemic chemotherapy alone as 1st-line treatment of malignant peritoneal mesothelioma Sgarbura et al. EquipeCG Jun 01, 2019
Inhibition of Ataxia-Telangiectasia Mutated and RAD3-Related (ATR) Overcomes Oxaliplatin Resistance and Promotes Antitumor Immunity in Colorectal Cancer Combès et al. EquipeNB 06 01, 2019
Strategies for clinical development of monoclonal antibodies beyond first-in-human trials: tested doses and rationale for dose selection Viala et al. EquipeCG Mar 06, 2018
Rational development of synergistic combinations of chemotherapy and molecular targeted agents for colorectal cancer treatment Tosi et al. EquipePM Aug 13, 2018
Is This Melanoma? A Quiz Veraldi et al. EquipeCG Jul 06, 2017
Clinical Development Strategies and Outcomes in First-in-Human Trials of Monoclonal Antibodies Tosi et al. EquipeMY Jul 01, 2015
Denosumab for treatment of hypercalcemia of malignancy Hu et al. EquipeCG Sep 2014
A phase II trial of sunitinib in patients with renal cell cancer and untreated brain metastases Chevreau et al. EquipeCG Feb 2014
13 Items


Who are we ?

Located in the Parc Euromédecine, the Institut de Recherche en Cancérologie de Montpellier (U1194) is located on the Val d'Aurelle Campus (ICM, Institut régional du Cancer Montpellier/ Val d'Aurelle).

U1194 Research Centre supported by Inserm, the University of Montpellier and the Institut du Cancer de Montpellier (ICM)

More                                                                                                                 Join us

Contact us

Institut de Recherche en Cancérologie de
Montpellier (U1194) - Campus Val d'Aurelle

208 avenue des Apothicaires
34298 Montpellier cedex 5 FRANCE

 

insermUM1ICM

© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés